Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for stroke survivors with rare clotting disorder: rivaroxaban vs warfarin

NCT ID NCT03684564

First seen Jun 02, 2026 · Last updated Jun 19, 2026 · Updated 3 times

Summary

This study tested whether the drug rivaroxaban works as well as warfarin to prevent further brain damage in people who have had a stroke due to antiphospholipid syndrome (APS), a condition that causes abnormal blood clotting. About 40 participants took either rivaroxaban or warfarin for 24 months. The main goal was to see if brain scans showed less damage over time. This is a phase 2 trial, meaning it's an early test of effectiveness and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Barts and the London Hospitals, Barts Health NHS Trust

    London, United Kingdom

  • Epsom and St Helier University Hospitals NHS Trust

    Epsom, United Kingdom

  • Hammersmith Hospital, Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Kings College Hospital NHS Foundation Trust

    London, United Kingdom

  • Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust

    Romford, United Kingdom

  • University College Hospitals NHS Foundation Trust

    London, United Kingdom

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome brain infarction brain ischemia ischemic stroke stroke disorder systemic lupus erythematosus transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.